Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: First Quarter 2012 (Three months ended March 31, 2012)
Filing Date: May 2, 2012
GSK is a leading research-based pharmaceutical and healthcare company. The results are reported in Sterling and are significantly influenced by exchange rate movements, particularly against the US Dollar, Euro, and Japanese Yen. The company utilizes "Core Results" to exclude non-recurring items such as restructuring costs, legal charges, and intangible asset amortization to provide a clearer view of underlying performance.
Key Financial Metrics
| Metric | Q1 2012 | Q1 2011 (Restated) |
|---|---|---|
| Total Turnover | £6,640 million | £6,585 million |
| Core Turnover Growth (CER) | 2% | - |
| Operating Profit (Total) | £2,037 million | £2,035 million |
| Core Operating Profit | £2,071 million | £2,044 million |
| Core Operating Margin | 31.2% | 31.0% |
| Profit After Taxation | £1,390 million | £1,584 million |
| Earnings Per Share (Total) | 26.7p | 30.0p |
| Core EPS | 27.3p | 25.9p |
| Net Cash Inflow from Operations | £1,012 million | £987 million |
| Net Debt | £8,877 million | £8,419 million |
Material Changes vs. Prior Period
- Revenue Growth: Total turnover increased 2% to £6,640 million. Pharmaceuticals and Vaccines turnover grew 2% to £5,304 million, while Consumer Healthcare grew 1% to £1,336 million.
- Regional Performance:
- US: Pharmaceuticals and Vaccines turnover grew 9% (CER), driven by new products and the Vesicare co-promotion agreement.
- Europe: Turnover declined 6% (CER) due to government austerity measures, price cuts (approx. 4.5 percentage point impact), and generic competition.
- EMAP: Turnover grew 2% (CER), though growth was dampened by instability in the Middle East/Africa.
- Japan: Turnover grew 4% (CER), supported by Cervarix and new product launches.
- Profitability: Core operating profit grew 3% (CER) to £2,071 million, reflecting improved operating leverage. However, total EPS decreased to 26.7p from 30.0p, primarily due to the absence of a £584 million profit on the disposal of Quest Diagnostics interests in Q1 2011.
- Cost Structure: Core R&D expenditure increased 4% to £892 million (13.4% of turnover) due to increased investment in the late-stage pipeline. Core SG&A costs rose to 30.7% of turnover, partly due to exchange losses on intercompany transactions.
Guidance, Outlook, and Risks
- Dividends: The Board declared a first interim dividend of 17 pence per share (up from 16 pence in Q1 2011).
- Share Repurchases: GSK repurchased £226 million of shares in Q1 2012 and expects total repurchases for the year to be between £2 billion and £2.5 billion.
- Pipeline Updates:
- Votrient: FDA approved for advanced soft tissue sarcoma.
- Nimenrix: European Commission granted marketing authorization.
- Albiglutide: Data from 7 of 8 Phase III studies support progression to regulatory filing.
- Dabrafenib: Phase III data in-house and sufficient to file.
- Divestments: GSK is actively divesting non-core OTC brands. Agreements were reached to sell European brands to Omega Pharma (£391 million) and international brands to Aspen Pharmacare (£164 million). The divestment of alli remains delayed due to supply interruptions.
- Risks and Contingencies:
- Legal: Aggregate provision for legal and other disputes stands at £2.6 billion. Significant proceedings include product liability, intellectual property, and government investigations.
- Exchange Rates: A strengthening Sterling against the Euro and Yen is expected to have an adverse impact on 2012 core EPS of approximately 1% if rates hold.
- Regulatory: Risks include patent expirations, generic competition, and potential withdrawal of regulatory approvals.
Investor Verification Checklist
- Core vs. Total Results: Verify the reconciliation of core results to total results, specifically the impact of the £236 million other operating income (disposal of North American OTC brands) and the absence of the Q1 2011 Quest Diagnostics disposal profit.
- Europe Exposure: Assess the sustainability of the 6% decline in European turnover driven by austerity and price cuts, and the specific impact on respiratory and vaccine sales.
- Divestment Timeline: Confirm the completion dates and final proceeds for the Omega Pharma and Aspen Pharmacare transactions, and the status of the alli divestment.
- Legal Provisions: Review the £2.6 billion legal provision and monitor developments in ongoing litigation and government investigations.
- Exchange Rate Sensitivity: Evaluate the impact of currency fluctuations on future earnings, given the company's significant exposure to the US Dollar, Euro, and Yen.